PIK3CA and non-small cell lung carcinoma: In clinical samples of NSCLC resistant to osimertinib as first- or second-line treatment, the incidence of PIK3CA gene mutations can reach 4%-11%, including mutations such as PIK3CA E545K, E542K, R88Q, N345K, and E418K (72–75).